Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | EIF4E | P06730 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 2/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14114868 | 0.87 | TTR (0.51) | TTRPTPRCSRD5A2POLBKMT2A | |
| SCHEMBL31156109 | 0.86 | TSHR (0.42) | TSHRTTRS1PR3PTPRCMRGPRX4 | |
| SCHEMBL3927793 | 0.82 | TSHR (0.59) | TSHRTTRPTPRCSRD5A2POLB | |
| SCHEMBL2043423 | 0.82 | RORC (0.51) | TTRPTPRCSRD5A2POLBKMT2A | |
| SCHEMBL13601695 | 0.82 | TTR (0.46) | TSHRTTRPTPRCSRD5A2POLB | |
| SCHEMBL2769863 | 0.80 | TSHR (0.71) | TSHRTTRPTPRCSRD5A2POLB | |
| SCHEMBL14089938 | 0.79 | ALDH1A1 (0.45) | TTRPTPRCSRD5A2POLBKMT2A | |
| SCHEMBL2744846 | 0.79 | TTR (0.46) | TSHRTTRPTPRCPOLBKMT2A | |
| SCHEMBL17272798 | 0.79 | TSHR (0.59) | TSHRTTRS1PR3SRD5A2MRGPRX4 | |
| SCHEMBL14089994 | 0.78 | CA12 (0.51) | TSHRTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2772484-B1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-06-28 | — | — | EP | disclosed |
| EP-2772484-B1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-06-28 | — | — | EP | disclosed |
| CN-103917524-B | Bicyclic heterocycles | ASTELLAS PHARMA INC. (JP) | 2016-05-04 | — | — | CN | disclosed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266840-B2 | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2772484-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2772484-A1 | BICYCLIC HETEROCYCLIC COMPOUND | Astellas Pharma Inc. (JP) | 2014-09-03 | — | — | EP | disclosed |
| CN-103917524-A | Bicyclic heterocyclic compound | ASTELLAS PHARMA INC | 2014-07-09 | — | — | CN | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140249151-A1 | BICYCLIC HETEROCYCLIC COMPOUND | HSD11B1, HSD17B11, HSD17B1 | TSHR 4385/4885TTR 2500/4885S1PR3 3542/4885 |
| US-20090298894-A1 | AMINO ACID COMPOUNDS | S1PR1, S1PR2, S1PR5 | TSHR 957/4885TTR 2102/4885S1PR3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.